Somaxon Pharmaceuticals Names Brian Dorsey VP of Manufacturing and Program Mgmt
13th Nov 2006, 22:53 GMT
Somaxon Pharmaceuticals appointed Brian Dorsey as VP of Manufacturing and Program Mgmt, a newly created position.
Somaxon Pharmaceuticals Names Brian Dorsey VP of Manufacturing and Program Mgmt related news:
- Diffusion Pharmaceuticals Strengthens Mgmt Team With Appointment of Matthew W Hantzmon as VP, Business Development — Government/ Industry Regulation News from StratCenter.com
- Pharmaceutical Companies Address Barriers to Portfolio Mgmt Success — Pharmaceuticals News from StratCenter.com
- Tacere Therapeutics Appoints VP, R&D — Pharmaceuticals News from StratCenter.com
- deCarta Names VP (deCarta) — CADwire.net - All CAD industry news
- CBS picks program VP — Variety.com
- Advanced Manufacturing Profiles Visibility Executive VP Stephen Carson — Press Release and Top News From 24-7 Press Release Newswire
- Milacron names McIlnay director — bizjournals.com Manufacturing:General headlines
- Health Integrated to Speak at World Research Group Summit on Disease Mgmt for Depression — Insurance/ Managed Care News from StratCenter.com
- Convergys names Handy senior VP — Latest news from Cincinnati Business Courier
- Spectrum Pharmaceuticals gets $5M milestone payment, settles with GlaxoSmithKline — bizjournals.com Health Care:Pharmaceuticals headlines
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress